

PATIENT GROUP DIRECTION (PGD)

SUPPLY OF LEVONORGESTREL 1500 MICROGRAM TABLET

By registered pharmacists for

Emergency Hormonal Contraception

In Community Pharmacy

Documentation details

Version no:	3.5
Valid from:	1 st April 2025
Review date:	1 st April 2027
Expiry date:	31 st March 2028

Change history

Version	Summary of Changes	Action by	Date
1.0		Stephen Woods	January 2014
2.0		Stephen Woods	February 2016
3.0	- Updated in line with new FSRH guidance published March 2017 - New recommendations on dosing including 3mg in women >70kg or BMI >26kg/m² - Change to action following vomiting – period to supply second tablet following vomiting has been extended from two to three hours.	Alicia Robson	December 2017
3.1	None	Alicia Robson	October 2019
3.2	- Moved PGD to national template - Added in temporary supply adjustment measures in view of COVID-19 pandemic. Sections updated include: - Quantity to be supplied - Patient advice/follow up treatment - Records	Tsz Shan Mak	June 2020
3.3	Removed link to FPA Emergency Contraception leaflet download as document currently not available.	Alicia Robson	June 2022

	Extra review date included (August 2022 – to review and potentially remove the option for remote consultations which were required during COVID-19 pandemic.		
3.4	- Updated to reflect CCG changes to ICB - Logo changed - CCG reference changed to NHS GM Salford locality - Updated link for online BNF - Link added for NICE CG30 - Temporary supply adjustment measures in view of COVID-19 pandemic changed to wording to support any future government directed infection prevention and control protocols. Sections updated include: - Quantity to be supplied - Patient advice/follow up treatment - Records	Tsz Shan Mak	May 2023
3.5	- PGD expiry date changed from 2 years to 3 years. - Updated broken links within references section	Tsz Shan Mak	Dec 2024

Glossary

Abbreviation	Definition
CPPE	Centre for Pharmacy Postgraduate Education
UPSI	Unprotected sexual intercourse
IUD	Intrauterine device
SPC	Summary of Product Characteristics
FSRH	Faculty of Sexual & Reproductive Healthcare

D

1. PGD template development

Developed/Reviewed by:	
Name	Designation
Dr Peter Budden	GP Prescribing Lead, NHS GM Salford locality
Claire Vaughan	Associate Director Clinical & Care Professional Leadership and Head of Medicines Optimisation, NHS GM Salford locality
Alicia Robson	Medicines Optimisation Pharmacist, NHS GM Salford locality
Tsz Shan Mak	Medicines Optimisation Pharmacist, NHS GM Salford locality

2. Organisational authorisations

The PGD is not legally valid until it has had the relevant organisational authorisation.

It is the responsibility of the organisation that has legal authority to authorise the PGD, to ensure that all legal and governance requirements are met. The authorising body accepts governance responsibility for the appropriate use of the PGD.

Salford City Council authorises this PGD for use by the services or providers listed below:

Authorised for use by the following organisation and/or services
Sexual health services provided by community pharmacies commissioned by Salford City Council
Limitations to authorisation
The Pharmacy Contractor is responsible for ensuring that only suitable Pharmacists sign up to this PGD and should maintain a record of the names of individual Pharmacists and evidence of the training received.

Organisational approval (legal requirement)			
Role	Name	Sign	Date
Director of Public Health, Salford City Council	Dr Muna Abdel Aziz		13/3/25
Additional signatories according to locally agreed policy			
Role	Name	Sign	Date
Doctor (Medical Director – Salford locality, NHS GM)	Dr Tom Regan		12/3/25
Senior Pharmacist (Head of Medicines Optimisation – Salford locality, NHS GM)	Jude Owens		12/3/25

Section 7 provides a registered health professional authorisation sheet. Individual professionals must be authorised by name to work to this PGD. Alternative authorisation sheets/templates may be used where appropriate in accordance with local policy.

3.Characteristics of staff

Qualifications and professional registration	• Pharmacist with current General Pharmaceutical Council registration • Work in a Community Pharmacy within Salford City Council area
Initial training	• Has undertaken training in the use of PGDs • Has undertaken training which enables the pharmacist to make a clinical assessment in order to establish the need and supply the treatment according to this PGD as detailed in the service specification. • Has satisfied the competencies appropriate to this PGD, as detailed in the Centre for Postgraduate Pharmacy Education (CPPE) and NHS Health Education England <i>Declaration of Competence for pharmacy services – Emergency Contraception with the use of a Patient Group Direction</i> document (https://www.cppe.ac.uk/services/docs/emergency%20contraception.pdf) • Is competent in the assessment of the individuals using Fraser guidelines
Competency assessment	It is essential that pharmacists complete and satisfy the competencies detailed in the CPPE and NHS Health Education England <i>Declaration of Competence for pharmacy services – Emergency Contraception Service with the use of a Patient Group Direction</i> document.
Ongoing training and competency	• The pharmacist should be aware of any change to the recommendations for the medicine listed. • Must be able to show regular update in the field of family planning and reproductive health care including emergency contraception. • Must assess and maintain their own competence on the medicine supplied under this PGD in line with the requirements contained within the <i>Declaration of Competence for pharmacy services – Emergency Contraception with the use of a Patient Group Direction</i> document. • It is the responsibility of the pharmacist to keep up-to-date with continuing professional development • It is the responsibility of the pharmacist to maintain their own competency to practice within this PGD. Further training may be necessary when the PGD is reviewed
<i>The decision to supply any medication rests with the individual registered health professional who must abide by the PGD and any associated organisation policies.</i>	

4. Clinical condition or situation to which this PGD applies

Clinical condition or situation to which this PGD applies	A patient requesting oral emergency contraception who presents within 72 hours of unprotected sexual intercourse (UPSI) or potential contraception failure
Criteria for inclusion Use BNF/BNFC/SPC. Take into account any clinical guidelines or policies that are available locally or nationally, e.g. BASHH/NICE/JCVI	Women with spontaneous menstrual cycles presenting within 72 hours of UPSI or potential contraception failure (e.g. condom failure, severe vomiting/diarrhoea whilst on oral hormonal contraception), and who: • Have no known contraindications to progestogen in their known medical history. • Understand the risks, benefits and side effects. • Meet Fraser guidelines, if under 16 years of age. <i>Note children under 13 years of age must be notified to the local Safeguarding Team; however, this should not prevent treatment if considered necessary under this PGD.</i> • Are competent to consent to treatment. • Have been offered the option of an intrauterine device (IUD). If referring for a post-coital intrauterine device, oral emergency hormonal contraception should be supplied if within PGD and acceptable to the patient. • Has reached the menarche Patient has received levonorgestrel emergency contraception but has vomited within three hours of taking it (provided they are still within 72 hours of UPSI).
Criteria for exclusion	• UPSI more than 72 hours ago. • Allergy/known intolerance to progestogen or other product ingredients. • Severe hepatic impairment. • Acute porphyrias • Confirmed pregnancy. (Suspected pregnancy should be excluded using a pregnancy test.) • Previous use of ulipristal emergency contraception in the last 5 days (<i>The effectiveness of ulipristal emergency contraception could be reduced if a progestogen (in this case – levonorgestrel) is taken in the 5 days after taking ulipristal</i>). • Women less than 21 days post-partum. Following termination of pregnancy, regard the date of termination as the last menstrual period. • Any other instances of UPSI within the same menstrual cycle. • Undiagnosed vaginal bleeding. • At risk of ectopic pregnancy (previous history of salpingitis or ectopic pregnancy) • Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption. • Third party requests. • Current contraception method used correctly. If the patient is receiving any concomitant medication or treatment, it is the responsibility of the healthcare professional identified in 'Characteristics of Staff' to ensure that treatment with the medicines detail in this PGD is appropriate. In case of any doubt, further advice must be sought from an appropriate healthcare professional (e.g.

	patient's GP, sexual health clinic doctor) and this must be recorded as having been sought before the medicine is given.
Cautions including any relevant action to be taken	- Severe intestinal malabsorption syndromes e.g. Crohn's disease, might impair the efficacy of levonorgestrel. Advise patient accordingly. - Active trophoblastic disease (until return to normal of urine and plasma gonadotrophin concentrations). - The small amount of levonorgestrel that appears in breast milk should not be harmful to the baby. However, patients should be advised to take levonorgestrel immediately after a breast feed, thus reducing the amount of drug the baby may take in the next feed. - If UPSI occurred in the 12 hours following a treatment dose of levonorgestrel as emergency contraception, the FSRH advises that further emergency contraception is not required. - The metabolism of levonorgestrel is enhanced by concomitant use of liver enzyme inducers. Drugs suspected of having the capacity to reduce the efficacy of levonorgestrel containing medication include <i>barbiturates (including primidone)</i>, <i>phenytoin</i>, <i>carbamazepine</i>, <i>herbal medicines containing Hypericum perforatum (St. John's Wort)</i>, <i>rifampicin</i>, <i>ritonavir</i>, <i>rifabutin</i>, <i>griseofulvin</i>. - Medicines containing levonorgestrel may increase the risk of ciclosporin toxicity due to possible inhibition of ciclosporin metabolism. - Interactions between levonorgestrel and patient's regular medication, in particular enzyme-inducing medication. <i>See Drug interactions.</i>
Action to be taken if the patient is excluded	- Refer to appropriate doctor or sexual health clinic. - Document all actions taken.
Action to be taken if the patient or carer declines treatment	- Make individual aware of the risks of not receiving treatment. - Refer to doctor or sexual health clinic. - Document all actions taken.
Arrangements for referral for medical advice	<i>Refer to the appropriate medical practitioner in the care pathway</i>

5. Description of treatment

Name, strength & formulation of drug	Levonorgestrel 1500 microgram tablet
Legal category	POM
Route / method of administration	Oral
Indicate any off-label use (if relevant)	In the following circumstances, levonorgestrel 1500 microgram may be used outside the terms of the product licence; such use is justified by current best practice (FSRH guidance): Enzyme- inducing medication can reduce the efficacy of oral emergency hormonal contraception. If the patient is currently receiving treatment with enzyme-inducing medication (or stopped taking enzyme-inducing medication up to four weeks ago) then

	they should always be offered the alternative of a copper intrauterine device which is unaffected by concomitant drug use. If levonorgestrel is preferable to the intrauterine device, the dose provided to the patient must be doubled to 3000micrograms to be taken immediately as a single dose. - Higher weight or BMI could reduce the effectiveness of levonorgestrel 1500 microgram. Therefore if a woman has a BMI >26kg/m² or weight >70kg it is recommended that a double dose of levonorgestrel (3000 micrograms) be given. A copper IUD is not affected by weight and BMI and women should be signposted to an appropriate provider for fitting of an IUD if appropriate and acceptable to the patient. - According to FSRH guidance, as there is no evidence to indicate levonorgestrel is not safe in pregnancy, it can be used more than once in the same cycle or can be used for a recent episode of UPSI even if there has been an earlier episode of UPSI outside the treatment window. - A repeat dose may be given within three hours of vomiting after taking levonorgestrel.
Dose and frequency of administration	One 1500mcg tablet to be taken as a single dose as soon as possible and no later than 72 hours after UPSI. Two 1500mcg tablets to be taken as a single dose as soon as possible, and no later than 72 hours after UPSI for women taking liver enzyme inducing drugs (or stopped taking enzyme-inducing medication in the last 28 days) Two 1500mcg tablets to be taken as a single dose for women with a BMI of > 26kg/m² or who weigh >70kg. <i>If patient experiences vomiting within three hours of taking levonorgestrel, a second supply is allowed providing it is taken within 72 hours of UPSI.</i>
Duration of treatment	Single episode of treatment – Although multiple supplies are possible to the same client within the same cycle, they should be fully assessed each time a supply is requested. This is not a substitute for on-going contraception and signposting advice should be given to all clients, regardless of how many times they have accessed emergency contraception. <i>See Dose and Frequency section.</i>
Quantity to be supplied	Single dose of levonorgestrel 1500 micrograms or 3000 micrograms to be supplied in a suitably labelled box. (Labelled in accordance with current legislation) Patients should be observed taking the medication unless they are breast feeding when they can be allowed to take away for later consumption if necessary, but this must occur within the 72 hour window. NB. In line with any future government directed infection prevention and control protocols, to reduce risk of transmission, pharmacists may use their professional judgement on how they provide emergency hormonal contraception. This is provided they take steps to minimise patient risk and are mindful of potential for abuse with due regard to safeguarding.

	Any provision and use of professional judgement must give due consideration to the latest advice given by the General Pharmaceutical Council and Royal Pharmaceutical Society. For example by telephone consultation and delivered to patient. Supply via this method meant that patient does not need to be observed taking the medication. The pharmacist should seek assurance from the patient that they will take the dose as soon as possible and within 120 hours of UPSI or potential contraception failure when taking away. Supplies made utilising this temporary adjustment should be recorded as such.												
Storage	Store below 25°C. Store in the original packaging to protect from moisture. Keep the blister in the outer carton to protect from light.												
Drug interactions	- If the patient is taking any concomitant medication or treatment it is the practitioner's responsibility to ensure that treatment with the drug detailed in this PGD is appropriate. (For drug interactions see Appendix 1 of BNF (https://bnf.nice.org.uk/interactions) or the SPC (http://www.medicines.org.uk/emc/) or contact the Medicine Information Service at Liverpool – telephone number inside front cover of BNF) - In the case of any doubt, further advice must be sought from an appropriate health professional and recorded as having been sought before the drug is given. - If the requirements of this PGD cannot be complied with, the patient must be referred to a suitable independent prescriber.												
Identification & management of adverse reactions	<table border="1"> <thead> <tr> <th colspan="2">Very common and common adverse effects</th></tr> </thead> <tbody> <tr> <td>Abdominal pain</td><td>Breast tenderness</td></tr> <tr> <td>Diarrhoea</td><td>Dizziness</td></tr> <tr> <td>Fatigue</td><td>Gastro-intestinal disturbances</td></tr> <tr> <td>Headache</td><td>Menstrual irregularities</td></tr> <tr> <td>Vomiting</td><td>Nausea</td></tr> </tbody> </table> For a full adverse effects profile, refer to the SPC (www.medicines.org.uk) or the most current edition of the BNF (https://bnf.nice.org.uk)	Very common and common adverse effects		Abdominal pain	Breast tenderness	Diarrhoea	Dizziness	Fatigue	Gastro-intestinal disturbances	Headache	Menstrual irregularities	Vomiting	Nausea
Very common and common adverse effects													
Abdominal pain	Breast tenderness												
Diarrhoea	Dizziness												
Fatigue	Gastro-intestinal disturbances												
Headache	Menstrual irregularities												
Vomiting	Nausea												
Management of and reporting procedure for adverse reactions	In the event of any adverse reaction: - Record the adverse reaction in the patient consultation note - Inform the patient's GP if the patient consents to this If appropriate report the adverse reaction under the Yellow Card scheme (forms can be found at the back of the BNF or completed online at http://yellowcard.mhra.gov.uk)												
Written information to be given to patient or carer	The patient should be given the following written information if appropriate:												

Patient advice / follow up treatment	- The product specific patient information sheet supplied with the medicine. The patient/carer should be given the following information verbally if appropriate and requested: - Effectiveness of method, dependent on length of time from UPSI/ potential contraceptive failure to treatment. - Beneficial effects, side effects and risks should be discussed. - How to take the pill correctly, preferably as an immediate dose in the pharmacy. Breast feeding mothers may be allowed to take away with them to allow them to feed their child before taking. This should only occur if it fits within the allowed time limits. - If vomiting occurs within three hours of taking, a repeat dose is required. - When to seek medical advice. - To refer to Sexual Health Clinic or GP if no/ light period up to 3 weeks after treatment. - Discuss on-going contraception including Quick Starting Contraception guidance (recommending starting contraception immediately after oral emergency hormonal contraception with additional protection as appropriate for the method used). - Discuss long-acting reversible contraception and give written information that is in line with NICE guidance, CG30 October 2005 https://www.nice.org.uk/guidance/cg30 - Supply and/or encourage use of condoms and reinforce the safer sex message. <i>NB: If supplies made utilising temporary adjustment in line with government directed infection prevention and control protocols, condoms could be delivered to patient along with levonorgestrel.</i> - Recommend sexually transmitted infections screening. - Advise where the patient will continue to use a hormonal method of contraception that they should use additional barrier contraceptives until onset of the next period. To patients taking enzyme-inducing medication or patients with a BMI>26kg/m2 or weight> 70kg - Advise on necessity for increased dose of levonorgestrel to 3000microgram (two tablets) (Off licence recommendation)
Records	The pharmacist must keep a record of the consultation as required in the service specification for a period of time in line with Records management: NHS code of practice (https://www.nhsx.nhs.uk/information-governance/guidance/records-management-code/) and service specification. The minimum required information to be collected is: - Informed consent has been given - Patient's name, address, date of birth. - Dose supplied. - Date administered/issued – if not, detail why. - Advice given. - Supply documented on Patient Medical Record. - ADRs documented. - Name, signature and GPhC number of pharmacist who supplied the medication.

	• Expiry date • Batch number • If under 16 years 'Fraser Competence Checklist' completed <i>NB: Supplies made utilising temporary adjustment in line with government directed infection prevention and control protocols, it should be recorded as such.</i> Records management: NHS Code of Practice recommends the following storage periods for Sexual Health paper records: • 8 years (in adults) or until 25th birthday in a child (age 26 if entry made when young person was 17), or 8 years after death. Computerised patients medication records can be used where considered appropriate. Data must be stored in accordance with Caldicott guidance and the Data Protection Act.
--	---

6.Key references

Key references	1. Faculty of Sexual and Reproductive Healthcare, Clinical Effectiveness Unit: • Emergency Contraception. Clinical Guidance, March 2017 (amended July 2023) Accessed 16th December 2024. • Contraceptive Choices for Young People. Clinical Guidance. March 2010, amended May 2019. Accessed 16th December 2024. 2. Manufacturers' Summaries of Product Characteristics (SPC) • Levonorgestrel 1.5mg tablet, Lupin Healthcare (UK) Ltd. Date of last revision of the text January 2022. Accessed 16th December 2024. 3. General Pharmaceutical Council • Standards for pharmacy professionals. May 2017. Accessed 16th December 2024. 4. Centre for Pharmacy Postgraduate Education • Declaration of competence for community pharmacy services; Emergency Contraception Service with the use of a Patient Group Direction. Accessed 16th December 2024.
----------------	---

7. Registered health professional authorisation sheet

Authorising manager

I confirm that the registered health professionals named above have declared themselves suitably trained and competent to work under this PGD. I give authorisation on behalf of INSERT NAME OF ORGANISATION for the above named health care professionals who have signed the PGD to work under it.

Name	Designation	Signature	Date

Note to authorising manager

Score through unused rows in the list of registered health professionals to prevent additions post managerial authorisation.

This authorisation sheet should be retained to serve as a record of those registered health professionals authorised to work under this PGD.